Skip to main
ANVS

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio Inc demonstrates a robust potential for growth, primarily driven by its innovative pipeline that addresses chronic and acute neurodegenerative diseases, particularly through its lead product, Buntanetap. Recent interim results from its clinical trials indicate a reduction in sAPP levels, which promises a significant opportunity for disease modification in Alzheimer's and Parkinson's patients, with plans to initiate a Phase 2 trial in late 2025. Furthermore, the company has established alignment with the FDA regarding the new drug application process, enhancing confidence in its developmental strategies and potential market entry, contingent on favorable trial results.

Bears say

Annovis Bio Inc faces significant financing risks, particularly as it operates with a very modest cash runway, which may necessitate dilutive capital-raising activities. The company's pipeline targets challenging neurodegenerative diseases like Alzheimer's and Parkinson's, which historically present high rates of clinical trial failures due to efficacy and safety concerns. Furthermore, the potential lack of FDA approval for product filings, as well as anticipated competition and pricing pressures, could hinder any future commercial success.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.